Retrospective Study in Sarcoma Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

514 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-04-18

Study Completion Date

2021-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objectives of this trial is to evaluate efficacy and safety of treatment with Trabectedin in a large cohort of German patients with soft tissue and bone sarcomas.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoma of Bone Sarcoma of Soft Tissue

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Drug therapy Treatment outcome Adult

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with histologically confirmed soft tissue or bone sarcomas treated with at least one cycle of Trabectedin in any line of therapy.
* Age ≥18years at start of therapy with Trabectedin
* Informed Consent
* Patients already deceased may be included when the treating physician is able to determine the presumptive consent

Exclusion Criteria

* No follow-up data available

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daniel Pink, MD

Role: PRINCIPAL_INVESTIGATOR

University Medicine Greifswald

Peter Reichardt, MD

Role: PRINCIPAL_INVESTIGATOR

Sarcoma Center Berlin-Brandenburg; HELIOS Hospital Berlin Buch

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Medicine Greifswald, Department of Internal Medicine C

Greifswald, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Pink D, Bertz-Lepel J, Busemann C, Bitz U, Reichardt P. Efficacy of trabectedin in patients with advanced or metastatic alveolar soft-part sarcoma. Onkologie. 2012;35(5):249-52. doi: 10.1159/000338342. Epub 2012 Apr 23.

Reference Type BACKGROUND

PMID: 22868503 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GISG-14

Identifier Type: -

Identifier Source: org_study_id